In this episode, Michael and Josh investigate Lung Oncology research presented at ASCO 23, specifically early lung cancer treatment. They discuss Perioperative Toripalimab, LAG3 inhibitor Relatlimab and the new novel agent BI 764532, a novel DLL3-targeting T cell engaged.

Studies:

NEOTORCH: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.36_suppl.425126

NEOPREDICT: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8500

DLL3-positive SCLC: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8502

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.